Price Reductions for 2014 Main Cycle

Summary of 1 April 2014 Price Reductions for 2014 Main Cycle by Drug / Manner of Administration / Percentage Reduction:

Summary of 1 April 2014 Price Reductions for 2014 Main Cycle

Drug

MOA

Percentage Reduction

Aciclovir

Oral

25.45%

Alendronic acid

Oral

28.02%

Amiodarone

Oral

14.55%

Amisulpride

Oral

22.92%

Amlodipine

Oral

31.35%

Amoxycillin

Oral

15.37%

Amoxycillin with clavulanic acid

Oral

14.14%

Atenolol

Oral

14.66%

Azithromycin

Oral

35.26%

Bicalutamide

Oral

13.98%

Bisoprolol

Oral

25.70%

Carvedilol

Oral

20.90%

Cefaclor

Oral

11.67%

Cefalotin

Injection

14.71%

Cefepime

Injection

20.45%

Ceftriaxone

Injection

35.88%

Cephalexin

Oral

12.07%

Cephazolin

Injection

47.71%

Ciprofloxacin

Oral

21.71%

Citalopram

Oral

31.86%

Clomipramine

Oral

10.84%

Clopidogrel

Oral

43.70%

Clopidogrel with aspirin

Oral

29.57%

Clozapine

Oral

15.77%

Cyproterone

Oral

15.02%

Diazepam

Oral

10.52%

Diclofenac

Oral

13.53%

Docetaxel

Injection

89.96%

Dothiepin

Oral

36.58%

Doxorubicin

Injection/intravesical

19.40%

Doxycycline

Oral

16.28%

Enalapril

Oral

10.92%

Epirubicin

Injection/intravesical

15.42%

Escitalopram

Oral

36.81%

Exemestane

Oral

15.01%

Famciclovir

Oral

38.60%

Felodipine

Oral

17.90%

Fentanyl

Transdermal

22.69%

Fluconazole

Injection

53.12%

Fluconazole

Oral

18.04%

Fludarabine

Injection

47.75%

Fluoxetine

Oral

20.91%

Flutamide

Oral

10.27%

Fluvoxamine

Oral

11.57%

Folinic acid

Injection

34.48%

Fosinopril

Oral

10.96%

Frusemide

Injection

10.01%

Frusemide

Oral

15.37%

Gabapentin

Oral

22.50%

Galantamine

Oral

13.55%

Gemcitabine

Injection

35.01%

Gemfibrozil

Oral

10.87%

Glucose

Injection

37.02%

Granisetron

Injection

44.94%

Granisetron

Oral

24.72%

Hydrocortisone

Rectal

10.24%

Hydroxocobalamin

Injection

20.95%

Hypromellose

Oral application

14.06%

Ipratropium

Inhalation

11.49%

Irinotecan

Injection

20.28%

Isosorbide mononitrate

Oral

10.06%

Isotretinoin

Oral

11.27%

Lactulose

Oral

16.24%

Lamivudine

Oral

15.75%

Lamotrigine

Oral

14.14%

Lansoprazole

Oral

15.80%

Latanoprost

Application to the eye

25.39%

Leflunomide

Oral

15.54%

Lercanidipine

Oral

18.37%

Levetiracetam

Oral

21.87%

Lisinopril

Oral

12.34%

Meloxicam

Oral

27.43%

Metformin

Oral

12.33%

Methotrexate

Injection

18.20%

Methylprednisolone

Injection

13.05%

Metronidazole

Injection

45.05%

Mirtazapine

Oral

27.54%

Mitozantrone

Injection

23.17%

Moclobemide

Oral

12.98%

Mometasone

Application

11.13%

Morphine

Injection

27.67% *

Nifedipine

Oral

11.15%

Norfloxacin

Oral

14.52%

Omeprazole

Oral

20.74%

Ondansetron

Injection

41.80%

Ondansetron

Oral

42.39%

Oxaliplatin

Injection

59.89%

Oxybutynin

Oral

11.66%

Paclitaxel

Injection

35.84%

Pamidronic acid

Injection

12.98%

Pantoprazole

Oral

33.83%

Paroxetine

Oral

16.15%

Perindopril

Oral

18.99%

Perindopril with indapamide

Oral

17.98%

Pindolol

Oral

10.89%

Pioglitazone

Oral

26.03%

Pravastatin

Oral

26.90%

Prochlorperazine

Oral

19.72%

Quinapril

Oral

10.59%

Rabeprazole

Oral

38.96%

Ramipril

Oral

17.36%

Ranitidine

Oral

18.81%

Risperidone

Oral

26.23%

Salbutamol

Inhalation

10.44%

Sertraline

Oral

33.35%

Simvastatin

Oral

39.97%

Sodium chloride

Injection

10.41%

Sotalol

Oral

12.04%

Sucralfate

Oral

10.03%

Sumatriptan

Oral

23.46%

Tamoxifen

Oral

15.79%

Terbinafine

Oral

19.01%

Ticlopidine

Oral

21.14%

Topiramate

Oral

18.60%

Topotecan

Injection

55.88%

Tramadol

Injection

13.89%

Tramadol

Oral

15.06%

Valaciclovir

Oral

56.52%

Valproic acid

Oral

20.50%

Vancomycin

Injection

20.90%

Vinorelbine

Injection

28.03%

For further information about ex-manufacturer level weighted average disclosed prices for each brand, and confirmation of brands with no reductions, please see the legal determination on the Comlaw.com website.

Price reductions will apply to brands listed in Schedule 1 of the determination. Those in Schedule 2 of the determination will not take a price disclosure reduction as their percentage difference was below 10%.  Any brands listed after 30 September 2013 for a pharmaceutical item that has a determination in Schedule 1 will also take the reduction on 1 April 2014.

Final prices applicable on 1 April 2014 will be available under the ‘Advance Notice of New Prices Resulting from EAPD Cycles’ link on this Web site from early March 2014.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on Monday, 23 December 2013.

* This reduction was not applied because the 27.67% average difference from the previous prices occurred only as a result of a price increase during the data collection period. See amending legislative instrument PB 8 of 2014.